TLR4 gene change and periodontitis in adults with end-stage kidney disease

The Role of Toll-like Receptor-4 in Periodontitis Patients With End-stage Renal Disease in a Sample of Egyptian Population

Observational Ain Shams University · NCT06755372

This project will test whether a specific TLR4 gene change (rs2149356) is linked to periodontitis in adults aged 30–60 who are on hemodialysis for end-stage kidney disease compared with otherwise healthy adults who also have periodontitis.

Quick facts

Study typeObservational
Enrollment100 (estimated)
Ages30 Years to 60 Years
SexAll
SponsorAin Shams University Academic / other
Locations1 site (Al Fayyum, Faiyum Governorate)
Trial IDNCT06755372 on ClinicalTrials.gov

What this trial studies

This observational study compares Egyptians aged 30–60 with end-stage renal disease on regular hemodialysis and stage II/III periodontitis to unrelated, systemically healthy controls who also have periodontitis. Participants will receive dental exams to confirm periodontitis staging and provide blood or saliva samples for genotyping of the TLR4 Gly/Thr (rs2149356) polymorphism. Key exclusions include current smokers, transplant recipients, people with malignancy, and those with systemic diseases other than type 2 diabetes (permitted in the ESRD group). The work is conducted at the Benha University Hospital hemodialysis center and is sponsored by Ain Shams University.

Who should consider this trial

Good fit: Ideal candidates are Egyptian adults 30–60 years old with stage II or III periodontitis who are either on regular hemodialysis for ESRD (including those with type 2 diabetes) or are systemically healthy controls without long-term medications.

Not a fit: People who are current smokers, have had a kidney transplant, have other systemic diseases (except diabetes in the ESRD group), or have a history of malignancy are excluded and unlikely to benefit from participating.

Why it matters

Potential benefit: If a link is found, testing for the TLR4 variant could help identify ESRD patients at higher risk of severe periodontitis and support earlier dental monitoring or preventive care.

How similar studies have performed: Previous studies have reported links between TLR4 variants and inflammatory conditions including periodontitis and CKD, but findings are inconsistent and the rs2149356 variant has limited prior testing in Egyptian ESRD patients.

Eligibility criteria

Show full inclusion / exclusion criteria
Group I: Healthy Subjects with Periodontitis

Inclusion Criteria:

Age: 30 to 60 years

Gender: Both male and female

Diagnosed with Periodontitis stage II and/or stage III

Systemically healthy, no history of systemic diseases

Not on long-term medications

Exclusion Criteria:

Smokers

Individuals with any systemic disease or long-term medication use

Group II: ESRD Patients with Periodontitis

Inclusion Criteria:

Age: 30 to 60 years

Gender: Both male and female

Diagnosed with end-stage renal disease (ESRD) on regular hemodialysis

Diagnosed with Periodontitis stage II and/or stage III

Unrelated Egyptians from a similar socioeconomic status, residing in the same geographical area

Underlying type 2 diabetes mellitus

Exclusion Criteria:

Individuals with kidney transplants

Individuals with systemic diseases other than diabetes

History of malignancy

Smokers

Where this trial is running

Al Fayyum, Faiyum Governorate

Study contacts

How to participate

  1. Review the eligibility criteria above with your treating physician.
  2. Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
  3. Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
Conditions PeriodontitisEnd-stage Renal DiseaseChronic Kidney DiseaseEnd-Stage Renal DiseaseToll-like Receptor 4Genetic Polymorphism
Last reviewed 2026-06-13 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.